By prescription and with individual adjustment by the physician; immediate- and extended-release forms exist. Not for self-medication.
In the largest network meta-analysis (Cortese 2018), methylphenidate is the first-choice drug in children and adolescents for its short-term efficacy-tolerability balance; it robustly improves the core symptoms of ADHD.
View the source (network meta-analysis) →⏱ 3 min read
First-line stimulant for ADHD (Ritalin, Concerta, Medikinet). Inhibits dopamine and norepinephrine reuptake; improves attention, impulsivity, and hyperactivity.
It blocks the dopamine and norepinephrine transporters in the prefrontal cortex, increasing the catecholaminergic signaling that supports attention and inhibitory control.
It is a first-line treatment in children. Response and dose are individualized; extended-release forms make a single daily dose possible. It should be combined with psychoeducational and lifestyle measures.
It requires a prior cardiovascular assessment and monitoring of blood pressure, heart rate, sleep, appetite and growth in children. It is a controlled substance because of its potential for misuse. Information, not medical advice: the indication and adjustment are for a professional.
Information, not medical advice. Prescription drug: its indication, dose, and monitoring are up to a health professional.